Cargando…

Testosterone and depressive symptoms during the late menopause transition

BACKGROUND: The menopause transition is associated with an increased risk of depression. While the mechanisms behind this increased risk are not well understood, the changing perimenopausal hormonal environment has been hypothesized to play a role. The current study examined the potential influence...

Descripción completa

Detalles Bibliográficos
Autores principales: Sander, Bethany, Muftah, Amira, Sykes Tottenham, Laurie, Grummisch, Julia A., Gordon, Jennifer L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8325283/
https://www.ncbi.nlm.nih.gov/pubmed/34330326
http://dx.doi.org/10.1186/s13293-021-00388-x
_version_ 1783731534803501056
author Sander, Bethany
Muftah, Amira
Sykes Tottenham, Laurie
Grummisch, Julia A.
Gordon, Jennifer L.
author_facet Sander, Bethany
Muftah, Amira
Sykes Tottenham, Laurie
Grummisch, Julia A.
Gordon, Jennifer L.
author_sort Sander, Bethany
collection PubMed
description BACKGROUND: The menopause transition is associated with an increased risk of depression. While the mechanisms behind this increased risk are not well understood, the changing perimenopausal hormonal environment has been hypothesized to play a role. The current study examined the potential influence of testosterone and the ratio of testosterone to estradiol as a potential contributor to depressed mood in the menopause transition. METHODS: Fifty non-depressed perimenopausal women ages 45–55 were recruited for this study. Once every 3 weeks, for a total of four times, the women completed the Centre for Epidemiological Studies-Depression (CES-D) scale for the measurement of depressive symptoms and provided a first-morning urine sample for the measurement of urinary testosterone as well as estrone-3-glucuronide (E1G), a urinary metabolite of estradiol. The week-to-week and mean effects of testosterone, E1G, and the testosterone/E1G ratio on CES-D score were examined. Self-reported sleep quality and vasomotor symptoms were also assessed at each of the four time points. RESULTS: Testosterone levels rose with increasing months since last menstrual period associated with testosterone levels (β(SE) = 175.3(63.2), p = .006), though this effect was moderated by body mass index (p for the interaction = .001) such that overweight women showed a less pronounced increase over time. Past and current smokers also had higher testosterone levels compared to never smokers. Week-to-week testosterone/E1G ratio was positively associated with CES-D score (β(SE) = 1.57(0.76), p = .041) but not sleep quality or vasomotor symptoms (ps > .05). Mean testosterone/E1G ratio was also positively associated with vasomotor symptom bother (β(SE) = 0.14(0.06), p = .018) and poorer sleep quality (β(SE) = − 0.34(0.09), p = .0001). CONCLUSION: These results suggest that, within the context of the menopause transition, times that are characterized by a higher testosterone-to-estradiol ratio may be associated with higher depressive symptoms. Perimenopausal women with a higher average ratio of testosterone relative to estradiol may also experience more sleep difficulties and vasomotor symptom bother.
format Online
Article
Text
id pubmed-8325283
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-83252832021-08-02 Testosterone and depressive symptoms during the late menopause transition Sander, Bethany Muftah, Amira Sykes Tottenham, Laurie Grummisch, Julia A. Gordon, Jennifer L. Biol Sex Differ Research BACKGROUND: The menopause transition is associated with an increased risk of depression. While the mechanisms behind this increased risk are not well understood, the changing perimenopausal hormonal environment has been hypothesized to play a role. The current study examined the potential influence of testosterone and the ratio of testosterone to estradiol as a potential contributor to depressed mood in the menopause transition. METHODS: Fifty non-depressed perimenopausal women ages 45–55 were recruited for this study. Once every 3 weeks, for a total of four times, the women completed the Centre for Epidemiological Studies-Depression (CES-D) scale for the measurement of depressive symptoms and provided a first-morning urine sample for the measurement of urinary testosterone as well as estrone-3-glucuronide (E1G), a urinary metabolite of estradiol. The week-to-week and mean effects of testosterone, E1G, and the testosterone/E1G ratio on CES-D score were examined. Self-reported sleep quality and vasomotor symptoms were also assessed at each of the four time points. RESULTS: Testosterone levels rose with increasing months since last menstrual period associated with testosterone levels (β(SE) = 175.3(63.2), p = .006), though this effect was moderated by body mass index (p for the interaction = .001) such that overweight women showed a less pronounced increase over time. Past and current smokers also had higher testosterone levels compared to never smokers. Week-to-week testosterone/E1G ratio was positively associated with CES-D score (β(SE) = 1.57(0.76), p = .041) but not sleep quality or vasomotor symptoms (ps > .05). Mean testosterone/E1G ratio was also positively associated with vasomotor symptom bother (β(SE) = 0.14(0.06), p = .018) and poorer sleep quality (β(SE) = − 0.34(0.09), p = .0001). CONCLUSION: These results suggest that, within the context of the menopause transition, times that are characterized by a higher testosterone-to-estradiol ratio may be associated with higher depressive symptoms. Perimenopausal women with a higher average ratio of testosterone relative to estradiol may also experience more sleep difficulties and vasomotor symptom bother. BioMed Central 2021-07-30 /pmc/articles/PMC8325283/ /pubmed/34330326 http://dx.doi.org/10.1186/s13293-021-00388-x Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Sander, Bethany
Muftah, Amira
Sykes Tottenham, Laurie
Grummisch, Julia A.
Gordon, Jennifer L.
Testosterone and depressive symptoms during the late menopause transition
title Testosterone and depressive symptoms during the late menopause transition
title_full Testosterone and depressive symptoms during the late menopause transition
title_fullStr Testosterone and depressive symptoms during the late menopause transition
title_full_unstemmed Testosterone and depressive symptoms during the late menopause transition
title_short Testosterone and depressive symptoms during the late menopause transition
title_sort testosterone and depressive symptoms during the late menopause transition
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8325283/
https://www.ncbi.nlm.nih.gov/pubmed/34330326
http://dx.doi.org/10.1186/s13293-021-00388-x
work_keys_str_mv AT sanderbethany testosteroneanddepressivesymptomsduringthelatemenopausetransition
AT muftahamira testosteroneanddepressivesymptomsduringthelatemenopausetransition
AT sykestottenhamlaurie testosteroneanddepressivesymptomsduringthelatemenopausetransition
AT grummischjuliaa testosteroneanddepressivesymptomsduringthelatemenopausetransition
AT gordonjenniferl testosteroneanddepressivesymptomsduringthelatemenopausetransition